STSA Insider Trading Activity and SEC Form 4 Filings
STSA insider trading summary
No open-market insider purchases or sales of Satsuma Pharmaceuticals, Inc. (STSA) have been reported on SEC Form 4 in the past 12 months.
Latest STSA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 8, 2023 | Shin Nippon Biomedical Laboratories, Ltd. | 10% Owner | Buy | $7.7M (8,423,732 @ $0.91) |
| Jun 6, 2023 | Ken Takanashi | Director | Buy | $20.1M (22,053,581 @ $0.91) |
| Jun 6, 2023 | Shin Nippon Biomedical Laboratories, Ltd. | 10% Owner | Buy | $20.1M (22,053,581 @ $0.91) |
| Nov 21, 2022 | Braden Michael Leonard | 10% Owner | Buy | $107K (150,000 @ $0.71) |
| Nov 15, 2022 | Braden Michael Leonard | 10% Owner | Buy | $189K (300,694 @ $0.63) |
| Nov 15, 2022 | Braden Michael Leonard | 10% Owner | Buy | $337K (531,000 @ $0.63) |
| Nov 14, 2022 | Commodore Capital LP | 10% Owner | Sell | $2.3M (3,250,000 @ $0.71) |
| Nov 14, 2022 | Braden Michael Leonard | 10% Owner | Buy | $3.9M (5,608,306 @ $0.69) |
| Nov 24, 2021 | Commodore Capital LP | 10% Owner | Buy | $16K (2,922 @ $5.42) |
| Nov 22, 2021 | Commodore Capital LP | 10% Owner | Buy | $55K (9,979 @ $5.49) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.